Healthcare provider profile · identity verified

Jianping Yang

Internal Medicine · BLOOMINGTON, MN · NPI 1932187861

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	587	155
Levothyroxine Sodium	Levothyroxine Sodium	468	110
Amlodipine Besylate	Amlodipine Besylate	429	108
Omeprazole	Omeprazole	403	103
Simvastatin	Simvastatin	388	98
Losartan Potassium	Losartan Potassium	353	91
Lisinopril	Lisinopril	276	74
Hydrochlorothiazide	Hydrochlorothiazide	254	70
Metoprolol Succinate	Metoprolol Succinate	243	61
Atenolol	Atenolol	166	46
Citalopram Hbr	Citalopram Hydrobromide	141	33
Gabapentin	Gabapentin	141	38
Metformin Hcl Er	Metformin Hcl	133	37
Escitalopram Oxalate	Escitalopram Oxalate	124	34
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	124	37
Furosemide	Furosemide	108	29
Alendronate Sodium	Alendronate Sodium	103	30
Sertraline Hcl	Sertraline Hcl	95	26
Pravastatin Sodium	Pravastatin Sodium	91	22
Metformin Hcl	Metformin Hcl	90	26
Allopurinol	Allopurinol	82	20
Trazodone Hcl	Trazodone Hcl	79	24
Rosuvastatin Calcium	Rosuvastatin Calcium	78	25
Glipizide Er	Glipizide	73	22
Fluticasone Propionate	Fluticasone Propionate	64	33
Eliquis	Apixaban	63	13
Ozempic	Semaglutide	61	12
Pantoprazole Sodium	Pantoprazole Sodium	61	18
Pregabalin	Pregabalin	60	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	59	15
Zolpidem Tartrate	Zolpidem Tartrate	55	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	49	13
Albuterol Sulfate Hfa	Albuterol Sulfate	48	27
Fluoxetine Hcl	Fluoxetine Hcl	47	13
Tamsulosin Hcl	Tamsulosin Hcl	47	15
Metoprolol Tartrate	Metoprolol Tartrate	45	12
Xarelto	Rivaroxaban	45	12
Estradiol	Estradiol	43	21
Baclofen	Baclofen	41	suppressed
Paroxetine Hcl	Paroxetine Hcl	40	11
Alprazolam	Alprazolam	38	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	37	suppressed
Carvedilol	Carvedilol	36	11
Synthroid	Levothyroxine Sodium	36	suppressed
Warfarin Sodium	Warfarin Sodium	36	11
Donepezil Hcl	Donepezil Hcl	35	11
Finasteride	Finasteride	35	suppressed
Irbesartan	Irbesartan	35	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	35	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	34	12
Potassium Chloride	Potassium Chloride	34	11
Spironolactone	Spironolactone	34	suppressed
Famotidine	Famotidine	33	suppressed
Ipratropium Bromide	Ipratropium Bromide	32	suppressed
Jardiance	Empagliflozin	32	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	31	suppressed
Duloxetine Hcl	Duloxetine Hcl	30	suppressed
Tramadol Hcl	Tramadol Hcl	30	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	29	suppressed
Bupropion Xl	Bupropion Hcl	28	suppressed
Mounjaro	Tirzepatide	28	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	28	21
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	27	suppressed
Prednisone	Prednisone	27	16
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	26	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	26	suppressed
Mirtazapine	Mirtazapine	25	suppressed
Tizanidine Hcl	Tizanidine Hcl	25	suppressed
Lorazepam	Lorazepam	24	suppressed
Trulicity	Dulaglutide	24	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	23	suppressed
Lovastatin	Lovastatin	23	suppressed
Ibandronate Sodium	Ibandronate Sodium	22	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	21	suppressed
Cephalexin	Cephalexin	20	15
Temazepam	Temazepam	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Bupropion Hcl Sr	Bupropion Hcl	19	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	18	18
Acyclovir	Acyclovir	17	12
Nystatin	Nystatin	17	11
Oxycodone Hcl	Oxycodone Hcl	17	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Clonazepam	Clonazepam	15	suppressed
Flecainide Acetate	Flecainide Acetate	15	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Topiramate	Topiramate	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	14
Clopidogrel	Clopidogrel Bisulfate	14	suppressed
Creon	Lipase/Protease/Amylase	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Fentanyl	Fentanyl	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Jantoven	Warfarin Sodium	13	suppressed
Propranolol Hcl Er	Propranolol Hcl	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Icosapent Ethyl	Icosapent Ethyl	12	suppressed
Klor-Con M20	Potassium Chloride	12	suppressed
Memantine Hcl Er	Memantine Hcl	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Oxycontin	Oxycodone Hcl	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Triazolam	Triazolam	12	suppressed
Anagrelide Hcl	Anagrelide Hcl	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Premarin	Estrogens, Conjugated	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error